574 related articles for article (PubMed ID: 30730563)
1. A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.
White CM
J Clin Pharmacol; 2019 Jul; 59(7):923-934. PubMed ID: 30730563
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol - therapeutic and legal aspects.
Vlad RA; Hancu G; Ciurba A; Antonoaea P; Rédai EM; Todoran N; Silasi O; Muntean DL
Pharmazie; 2020 Oct; 75(10):463-469. PubMed ID: 33305718
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol Adverse Effects and Toxicity.
Huestis MA; Solimini R; Pichini S; Pacifici R; Carlier J; Busardò FP
Curr Neuropharmacol; 2019; 17(10):974-989. PubMed ID: 31161980
[TBL] [Abstract][Full Text] [Related]
4. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
5. Clinicians' Guide to Cannabidiol and Hemp Oils.
VanDolah HJ; Bauer BA; Mauck KF
Mayo Clin Proc; 2019 Sep; 94(9):1840-1851. PubMed ID: 31447137
[TBL] [Abstract][Full Text] [Related]
6. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.
Mead A
Epilepsy Behav; 2017 May; 70(Pt B):288-291. PubMed ID: 28169144
[TBL] [Abstract][Full Text] [Related]
7. Regulatory Status of Cannabidiol in the United States: A Perspective.
Corroon J; Kight R
Cannabis Cannabinoid Res; 2018; 3(1):190-194. PubMed ID: 30283822
[TBL] [Abstract][Full Text] [Related]
8. Social media surveillance for perceived therapeutic effects of cannabidiol (CBD) products.
Tran T; Kavuluru R
Int J Drug Policy; 2020 Mar; 77():102688. PubMed ID: 32092666
[TBL] [Abstract][Full Text] [Related]
9. The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study.
Reithmeier D; Tang-Wai R; Seifert B; Lyon AW; Alcorn J; Acton B; Corley S; Prosser-Loose E; Mousseau DD; Lim HJ; Tellez-Zenteno J; Huh L; Leung E; Carmant L; Huntsman RJ
BMC Pediatr; 2018 Jul; 18(1):221. PubMed ID: 29981580
[TBL] [Abstract][Full Text] [Related]
10. The cannabidiol conundrum: potential benefits and risks of cannabidiol products for children.
Singer L; Tokish H; Park F; Campisi C; Milanaik RL
Curr Opin Pediatr; 2020 Feb; 32(1):198-205. PubMed ID: 31833952
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol and Other Cannabinoids: From Toxicology and Pharmacology to the Development of a Regulatory Pathway.
Koturbash I; MacKay D
J Diet Suppl; 2020; 17(5):487-492. PubMed ID: 32715797
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Cannabidiol on Psychiatric and Medical Conditions.
Oberbarnscheidt T; Miller NS
J Clin Med Res; 2020 Jul; 12(7):393-403. PubMed ID: 32655732
[TBL] [Abstract][Full Text] [Related]
13. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.
Fasinu PS; Phillips S; ElSohly MA; Walker LA
Pharmacotherapy; 2016 Jul; 36(7):781-96. PubMed ID: 27285147
[TBL] [Abstract][Full Text] [Related]
14. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
[TBL] [Abstract][Full Text] [Related]
15. Assessing the role of serotonergic receptors in cannabidiol's anticonvulsant efficacy.
Pelz MC; Schoolcraft KD; Larson C; Spring MG; López HH
Epilepsy Behav; 2017 Aug; 73():111-118. PubMed ID: 28624721
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol: pharmacology and therapeutic targets.
Britch SC; Babalonis S; Walsh SL
Psychopharmacology (Berl); 2021 Jan; 238(1):9-28. PubMed ID: 33221931
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Porcari GS; Fu C; Doll ED; Carter EG; Carson RP
Epilepsy Behav; 2018 Mar; 80():240-246. PubMed ID: 29429908
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
Franco V; Perucca E
Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
[TBL] [Abstract][Full Text] [Related]
19. Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies.
Silmore LH; Willmer AR; Capparelli EV; Rosania GR
Pharmacotherapy; 2021 Apr; 41(4):405-420. PubMed ID: 33583102
[TBL] [Abstract][Full Text] [Related]
20. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
